Huang James, 03 Life Sciences Disclose Significant Adagene Stake

TL;DR

**Huang James and Panacea funds just revealed a big stake in Adagene, watch for potential influence.**

AI Summary

On January 18, 2024, Huang James, associated with 03 Life Sciences, filed an SC 13G indicating a significant ownership stake in Adagene Inc. (NASDAQ: ADAG). This filing, under Rule 13d-1(c), signals that Huang James and his affiliated group, including Panacea Innovation Ltd and Panacea Venture Healthcare Fund II, now hold a substantial position in the pharmaceutical company. This matters to investors because large institutional or individual holdings can influence company direction and signal confidence (or lack thereof) in the stock's future performance.

Why It Matters

This filing reveals a notable ownership position by a key individual and associated funds, which can impact investor sentiment and potentially influence Adagene's strategic decisions.

Risk Assessment

Risk Level: low — This filing indicates a significant ownership stake, which is generally a neutral to positive signal, not an immediate risk.

Analyst Insight

Investors should monitor future filings from Huang James and the Panacea group for any changes in their Adagene Inc. holdings, as significant increases or decreases could signal their evolving outlook on the company.

Key Numbers

• January 18, 2024 — Date of Event (The date that triggered the filing requirement.)
• 005329 107 — CUSIP Number (The CUSIP number for Adagene's American Depositary Shares (ADSs), which are quoted on NASDAQ under 'ADAG'.)
• US$0.0001 — Par Value per Share (The par value of Adagene's ordinary shares.)

Key Players & Entities

• Huang James (person) — filer of the SC 13G
• Adagene Inc. (company) — the subject company of the filing
• 03 Life Sciences (company) — organization name associated with the filer
• PANACEA INNOVATION LTD (company) — group member associated with the filer
• PANACEA VENTURE HEALTHCARE FUND II GP COMPANY, LTD. (company) — group member associated with the filer
• PANACEA VENTURE HEALTHCARE FUND II, L.P. (company) — group member associated with the filer

Forward-Looking Statements

• The significant stake disclosed by Huang James and the Panacea funds could lead to increased investor confidence in Adagene Inc. (Adagene Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — ne quarter ordinary shares, par value US$0.0001 per share. The information required i

Filing Documents

• d726976dsc13g.htm (SC 13G) — 90KB
• d726976dex99.htm (EX-99) — 6KB
• 0001193125-24-010782.txt ( ) — 97KB

From the Filing

SC 13G 1 d726976dsc13g.htm SC 13G SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Adagene Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) 005329 107** (CUSIP Number) January 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. ** There is no CUSIP number assigned to the ordinary shares. CUSIP number 005329 107 has been assigned to the American depositary shares (ADSs) of the Issuer, which are quoted on NASDAQ Stock Market under the symbol ADAG. Each ADS represents one and one quarter ordinary shares, par value US$0.0001 per share. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G1933S101 Schedule 13G Page 1 of 9 1 Names of Reporting Persons Panacea Venture Healthcare Fund I I, L.P. 2 Check the Appropriate Box if a Member of a Group (a) (b) 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 2 , 750 , 000 7 Sole Dispositive Power 0 8 Shared Dispositive Power 2 , 750 , 000 9 Aggregate Amount Beneficially Owned by Each Reporting Person 2 , 750 , 000 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 5.0 % 12 Type of Reporting Person PN CUSIP No. 005329 107 Schedule 13G Page 2 of 9 1 Names of Reporting Persons Panacea Venture Healthcare Fund II GP Company, Ltd. 2 Check the Appropriate Box if a Member of a Group (a) (b) 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 2 , 750 , 000 7 Sole Dispositive Power 0 8 Shared Dispositive Power 2 , 750 , 000 9 Aggregate Amount Beneficially Owned by Each Reporting Person 2 , 750 , 000 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 5.0 % 12 Type of Reporting Person CO CUSIP No. 005329 107 Schedule 13G Page 3 of 9 1 Names of Reporting Persons Panacea Innovation Limited 2 Check the Appropriate Box if a Member of a Group (a) (b) 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 2 , 750 , 000 7 Sole Dispositive Power 0 8 Shared Dispositive Power 2 , 750 , 000 9 Aggregate Amount Beneficially Owned by Each Reporting Person 2 , 750 , 000 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 5.0 % 12 Type of Reporting Person CO CUSIP No. 005329 107 Schedule 13G Page 4 of 9 1 Names of Reporting Persons James Huang 2 Check the Appropriate Box if a Member of a Group (a) (b) 3 SEC Use Only 4 Citizenship or Place of Organization Republic of China Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 2 , 750 , 000 7 Sole Dispositive Power 0 8 Shared Dispositive Power 2 , 750 , 000 9 Aggregate Amount Beneficially Owned by Each Reporting Person 2 , 750 , 000 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 5.0 % 12 Type of Reporting Person IN CUSIP No. 005329 107 Schedule 13G Page 5 of 9 ITEM 1. (a) Name of Issuer: Adagene Inc. (the Issuer). (b) Address of Issuers Principal Executive Offices: 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 Peoples Republic of China ITEM 2. (a) Name of Person Filing: Each of the following is hereinafter individually referred to as a Reporting P

View Full Filing

View this SC 13G filing on SEC EDGAR